Latest research on Paricalcitol

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Latest findings

The type of treatment based on the administration of nutritional Vitamin D, Calcitriol, Paricalcitol, Calcimimetics, Calcium and non-Calcium based phosphate binders was done following the demands of each patient. [source, 2016]
The association between Paricalcitol and serum Calcium level was modest. [source, 2016]
Calcitriol and Paricalcitol were also associated to values of PTH, however it was not as strong as the PTH-calcimimetics association. [source, 2016]
Two Vitamin D treatment groups (one PBS group and one LPS group) were treated with the Vitamin D analog Paricalcitol (Sigma-Aldrich) dissolved in propylene (glycol:ethanol, 90:10; 0.5 µg/kg body weight) through intra-peritoneal injection 30 min prior to LPS or PBS treatment. [source, 2016]
Besides the recommendation to reduce the dietary intake of phosphorus, many drugs are currently available for the treatment of CKD-MBD; they include vitamin D sterols (Calcitriol, Cholecalciferol, Ergocalciferol), active vitamin D analogs (Paricalcitol, doxercalciferol, alfacalcidol), calcimimetics (cinacalcet), and phosphate binders. [source, 2016]
Following phosphate control, Calcitriol, Paricalcitol and cinacalcet treatment have started. [source, 2016]
Despoina et al. successfully treated CUA in a 57-year-old woman, using cinacalcet and Paricalcitol systemically and autologous growth factors locally (4). [source, 2016]
Therefore, Vitamin D receptor activators (VDRA), such as Calcitriol, Paricalcitol, or doxercalciferol, have been developed to treat osteoporosis, chronic kidney disease-mineral and bone disorder (CKD-MBD), and can also reduce podocyte injury, modulate immune responses, and improve insulin sensitivity [3–6]. [source, 2016]
The Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study demonstrated that addition of Paricalcitol to an inhibitor of the rennin-angiotensin-aldosterone system (RAAS) safely lowered residual albuminuria in patients with diabetic nephropathy [7]. [source, 2016]
However, patients given high-dose Paricalcitol (2 μg daily) experienced significant declines in estimated glomerular filtration rate (eGFR). [source, 2016]